Compare Capri Holdings Ltd (CPRI) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Inovio Pharmaceuticals Inc — how do they compare? Capri Holdings Ltd trades at $14.95 (market cap $1.67B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Capri Holdings Ltd is far larger — about 14.9× Inovio Pharmaceuticals Inc's market cap, and Capri Holdings Ltd is more actively traded (3,722,279 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| CPRI | INO | |
|---|---|---|
Market Cap | $1.67B | $112.19M |
Volume | 3,722,279 | 3,201,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $2.65 |
52-Week Low | $12.71 | $0.66 |
Typical Hold Time | 41 Days | 43 Days |
Enterprise Value | $2.95B | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.68, up 1.66% today, with a bullish technical signal from moving averages. The stock has beaten EPS estimates in recent quarters, but faces fundamental headwinds with revenue declining to $4.44B in 2025 and a net loss of $1.18B. Analyst consensus is a $20.57 price target, with 44% buy ratings. Recent news highlights brand revitalization efforts and second-half growth expectations from management commentary at the Goldman Sachs conference.
The outlook balances low valuation multiples against operational challenges. Investment appeal lies in potential margin improvement and brand turnaround, but risks include sustained revenue weakness, high debt levels, and competitive pressures in the luxury sector. The stock's recovery hinges on execution of the Michael Kors reset and macroeconomic support for consumer discretionary spending.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
